


(F.No. 37001/2020/Div.III/NPPA)
Government of India
Ministry of Chemicals & Fertilizers
Department of Pharmaceuticals
National Pharmaceuticals Pricing Authority

5th /3rd Floor,
YMCA Cultural Centre Building,
1, Jai Singh Road, New Delhi-110001
Date the **25th March, 2020**

ORDER

In pursuance to directions given by Department of Pharmaceuticals, the drug manufacturers of FDC namely 'Lopinavir & Ritonavir' (200 Mg+50 Mg.) are hereby directed, in public interest, in order to deal with the situation arising out of COVID-19, to maintain the stock level of said FDC at least 2.20 Crore tablets at any point of time and also to ensure sufficient availability of the said FDC till further orders. The drug manufacturers will maintain stock of said FDC as indicated against the concerned company's name below.

2. This issues with approval of competent authority.


(Manjesh Porwal)
Dy. Director (Enf.)

To,

1. Drug Manufacturers:- For compliance of direction given above.
 - i. Mylan Laboratories Ltd. (140 Lakhs Tablets)
 - ii. Aurobindo Pharma Ltd. (40 Lakhs Tablets)
 - iii. Cipla Ltd. (40 Lakhs Tablets)

Copy for information to:-

1. PSO to Secretary (Pharma) (w.r.t. Directions issued dated 19th March, 2020)
2. Sr. PPS to Secretary (Health)
3. Director General, ICMR
4. Sr. PPS to Chairman, NPPA
5. PPS to JS (Policy), Deptt. of Pharmaceuticals